Your browser doesn't support javascript.
loading
In Vitro Metabolism of 2-Methoxy-N-[3-[4-[3-methyl-4-[(6-methyl- 3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide (CP-724,714) by Aldehyde Oxidase and Predicting Its Percent Contribution Relative to CYP-Mediated Metabolism.
Inoue, Kazuko; Kikuchi, Kiyomi; Takahashi, Kazumi; Hitaoka, Seiji; Kusano, Kazutomi; Komori, Takafumi.
Afiliação
  • Inoue K; Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd., Tsukuba, Japan, (K.I., K.K., K.T., Ka.K., T.K.) and Emerging Modality Generation Department, Discovery Evidence Generation Function, DHBL, Eisai Co., Ltd., Tsukuba, Japan (S.H.) k12-inoue@hhc.eisa
  • Kikuchi K; Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd., Tsukuba, Japan, (K.I., K.K., K.T., Ka.K., T.K.) and Emerging Modality Generation Department, Discovery Evidence Generation Function, DHBL, Eisai Co., Ltd., Tsukuba, Japan (S.H.).
  • Takahashi K; Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd., Tsukuba, Japan, (K.I., K.K., K.T., Ka.K., T.K.) and Emerging Modality Generation Department, Discovery Evidence Generation Function, DHBL, Eisai Co., Ltd., Tsukuba, Japan (S.H.).
  • Hitaoka S; Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd., Tsukuba, Japan, (K.I., K.K., K.T., Ka.K., T.K.) and Emerging Modality Generation Department, Discovery Evidence Generation Function, DHBL, Eisai Co., Ltd., Tsukuba, Japan (S.H.).
  • Kusano K; Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd., Tsukuba, Japan, (K.I., K.K., K.T., Ka.K., T.K.) and Emerging Modality Generation Department, Discovery Evidence Generation Function, DHBL, Eisai Co., Ltd., Tsukuba, Japan (S.H.).
  • Komori T; Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Unit, DHBL, Eisai Co., Ltd., Tsukuba, Japan, (K.I., K.K., K.T., Ka.K., T.K.) and Emerging Modality Generation Department, Discovery Evidence Generation Function, DHBL, Eisai Co., Ltd., Tsukuba, Japan (S.H.).
Drug Metab Dispos ; 51(8): 962-969, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37188528
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema Enzimático do Citocromo P-450 / Aldeído Oxidase Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Drug Metab Dispos Assunto da revista: FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema Enzimático do Citocromo P-450 / Aldeído Oxidase Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Drug Metab Dispos Assunto da revista: FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article